Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Volume growth of AMGN's key drugs like Prolia, Repatha and Evenity is expected to have been partially offset by ...

James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith ... compelling survival benefit in B-ALL. IMDELLTRA, showing impressive efficacy and hard to treat ...

Amgen posted Q4 sales of $9.1 billion, up 11%, surpassing forecasts. EPS beat estimates, and analysts remain optimistic about growth prospects in 2025.

James Bradner; Executive Vice President - Research and Development; Amgen Inc Peter Griffith ... frontline treatment and demonstrating compelling survival benefit in B-ALL. IMDELLTRA, showing ...

Biosimilars have been on the market in Europe since 2007 but have had a larger impact on Amgen since 2019 as US exposure intensifies. Pressure on Prolia/Xgeva is coming in 2025. Amgen's pipeline had ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.